FDA Import Ban Hits Sinopep Subsidiary, Suspending Chinese Peptide API Sales to the US

The FDA has placed a subsidiary of Sinopep — a major Chinese manufacturer of peptide active pharmaceutical ingredients — under an import ban, suspending all of the company's peptide API sales into the US market, according to industry reports published September 22, 2026. The enforcement action is the sharpest move yet in an escalating campaign against the Chinese peptide ingredient supply chain that feeds the American GLP-1 market.

What Happened

The ban. The reported import ban stops Sinopep's subsidiary from shipping peptide active pharmaceutical ingredients into the United States. Products covered by such bans are typically detained at the border without physical examination — the standard mechanism the FDA uses when it loses confidence in a foreign manufacturer's compliance.

The backdrop. The action lands during a week of extraordinary political pressure on Chinese GLP-1 ingredient suppliers. Alabama's Steve Marshall warned federal officials about a Chinese "national security threat" in the pharmaceutical supply chain on September 18. Missouri's attorney general sounded the alarm over Chinese ingredients used in popular weight-loss drugs on September 21. And on September 22, officials from 20 states joined warnings about Chinese GLP-1 drug suppliers — the same day the Sinopep ban was reported.

Who Is Affected

• US buyers of Sinopep API — brands and research-chemical sellers that sourced peptide powders from the affected subsidiary now face immediate supply interruption.
• Downstream sellers — products formulated with API of uncertain provenance may already be circulating.
• The research community — labs relying on bulk Chinese peptide imports should expect detained shipments and rerouted sourcing, conditions under which quality control historically slips.
• State regulators — twenty states are now formally pressing the supply-chain issue.

Timeline

• September 18, 2026 — Warning to federal officials about a Chinese "national security threat" in the pharmaceutical supply chain.
• September 21, 2026 — Missouri's attorney general raises alarm over Chinese ingredients in popular weight-loss drugs.
• September 22, 2026 — Officials across 20 states warn about Chinese GLP-1 suppliers; the Sinopep subsidiary import ban is reported the same day.
• Earlier this month — Calls intensified to shut down the FDA's "Green List" after a listed Chinese manufacturer was caught relabeling unapproved semaglutide API from an unlisted facility.

What This Means for Researchers

• Detention without physical examination means shipments tied to the banned maker can be refused at the border on sight.
• Enforcement is shifting from firm-level trust to shipment-level scrutiny — origin documentation, lot records, and chain of custody now decide admissibility.
• Expect rerouting. When a major API source is cut off, some sellers quietly switch origins mid-stream — precisely the moment analytical verification matters most.
• The lesson of this month's enforcement wave: provenance claims are not a substitute for lab verification.

How to Verify Your Peptides

Independent testing is the only reliable signal in a disrupted supply chain:

• How peptide testing works — HPLC and LC-MS fundamentals
• Semaglutide testing — purity and identity checks for the most-affected compound class
• Choosing a third-party lab

Safe Alternatives

• Buy from suppliers that publish batch-level third-party test results — start with the PepsReview vendor directory.
• Cross-check compound research data before purchasing — browse the peptide pages.

Sources

Industry reports and regulatory announcements, September 2026.